Instituto Bioclon Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Mexico City Mexico (1990)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2004
NCT01599936
First Marketed Drug
2015
crotalidae immune f(ab')2 (equine) (Anavip)
First NDA Approval
2015
crotalidae immune f(ab')2 (equine) (Anavip)
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Bioclon | Instituto Bioclon S.A. de C.V.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bites and Stings (Phase 3)

Blood Coagulation Disorders (Phase 2)

Hemostatic Disorders (Phase 2)

Poisoning (Phase 3)

Scorpion Stings (Phase 3)

Snake Bites (Phase 4)

Spider Bites (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 7